Conference Coverage

L-Selectin Level May Help Stratify Patients at Risk of PML


 

References

Treatment decisions are influenced by unchangeable factors, such as previous immune suppression, and dynamic biomarkers, such as treatment duration and JCV antibody seropositivity. “Then you have two additional parameters that might be helpful for individual treatment decisions: JCV index and L-selectin,” concluded Dr. Wiendl.

Erik Greb

Pages

Recommended Reading

Age and DMT Exposure May Predict Conversion From Clinically Isolated Syndrome to MS
MDedge Neurology
Sodium Intake Is Linked to Increased Disease Activity in MS
MDedge Neurology
Watch for PML after switching from natalizumab to fingolimod
MDedge Neurology
Computerized Cognitive Test May Be a Valid Assessment for Patients With MS
MDedge Neurology
More Than 45 Novel MS Susceptibility Variants Are Identified
MDedge Neurology
Specialty drug coupons - a double-edged sword of improved adherence, increased costs
MDedge Neurology
Does MS Begin With Radiologically Isolated Syndrome?
MDedge Neurology
Specialty drugs: High cost, high value
MDedge Neurology
Lower frequency glatiramer acetate regimen appears safer
MDedge Neurology
MS overrepresented in depression, bipolar; schizophrenia possibly protective
MDedge Neurology